QUICK ANSWER · AEO / GEO
LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is LL-37?
LL-37 is described pharmacologically as Cathelicidin host-defence peptide. LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety.
Does LL-37 have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is LL-37 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.